Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients

Table 1 Demographic and baseline characteristics n (%)

Triple therapy: Peg-IFNα2a + Ribavirin +Protease inhibitor,	125
Telaprevir	90 (72)
Boceprevir	35 (28)
Ribavirin dosage mg/kg, mean (SD)	14.4 (2.1)
Age, yr, mean (SD)	56.2 (9.7)
Gender
Male	81 (64.8)
Female	44 (35.2)
HCV genotype
1a	39 (31.2)
1b	71 (56.8)
Undetermined subtype 1	15 (12)
IL28B genotype (rs12979860)
C/T or T/T	88 (84.6)
Viral load, mean (log10 IU/ mL)	6.3 (0.7)
Prior response to anti-viral therapy
Relapsers	46 (37.1)
Null-responders	78 (62.9)
Liver fibrosis grade
Metavir F3	35 (28)
Metavir F4	90 (72)
Child-Pugh score
A	123 (98.4)
B	1 (0.8)
C	1 (0.8)
Liver stiffness values (kPa)
Mean (SD)	17.5 (10.3)
Median (IQR)	14.3 (10.4-20.6)
Oesophageal varices
None	92 (75.4)
Grade 1	16 (13.1)
Grade 2 or 3	14 (11.5)
Mean hemoglobin level (g/dL, mean (SD)	15.1 (1.6)
Mean platelet count × 103/mm3, mean (SD)	165.69 (64.9)
Mean neutrophil count × 103/mm3, mean (SD)	3.4 (1.2)

Relapsers were defined as patients who had undetectable levels of HCV RNA at the end of prior treatment and subsequently relapsed. Null-responders failed to achieve a decline of at least 2 log HCV RNA IU/mL during peg-INF α2a + ribavirin treatment after a minimum duration of 24 wk. Peg-INF: Pegylated-interferon; HCV: Hepatitis C virus; IQR: Inter-quartile range.